FOXP3 is a transcription factor necessary and sufficient for induction of the immunosuppressive functions in regulatory T lymphocytes. Its expression was first considered as specific of this cell type, but FOXP3 can also be transiently expressed in T-cell antigen receptoractivated human nonregulatory T cells. Recent data indicate that FOXP3 is also expressed by some nonlymphoid cells, in which it can repress various oncogenes that are restored following FOXP3 deletion or mutation. This review summarizes major advances in (1) the understanding of Foxp3 functions in human regulatory T cells, (2) the prognostic significance of Foxp3-expressing T cells in human malignancies and (3) the significance of Foxp3 expression in human tumor cells.
Introduction
FOXP3 belongs to the family of forkhead box (FOX) transcription factors that are characterized by a highly conserved forkhead (FKH) DNA-binding domain described as a winged helix. The forkhead gene product was initially identified in the fruit fly Drosophila melanogaster as factor required for the terminal pattern formation in the terminal regions of the embryo (Weigel et al., 1989) . Several members of the FOX family were later found to have crucial roles in various aspects of immune regulation (Coffer and Burgering, 2004) . The Foxp3 gene was first discovered by studying the scurfy mice bearing a lethal X-linked recessive immunodysregulation (Brunkow et al., 2001) . Foxp3 was found to be a master regulator in the development and function of regulatory T cells (Treg) (Schubert et al., 2001; Fontenot et al., 2003; Hori et al., 2003) . Tregs were initially defined as immunosuppressive CD4 þ T cells expressing constitutively the a-subunit of the interleukin (IL)-2 receptor (CD25) on their surface (Sakaguchi, 2000) . The nuclear expression of FOXP3 is now considered as the most specific marker for these cells (Sakaguchi, 2005) . However, FOXP3 can be expressed transiently on human nonregulatory CD4 þ T cells upon T-cell antigen receptor (TCR) activation. Furthermore, recent reports demonstrate that Foxp3 is also expressed in nonlymphocytic normal or cancer cells, suggesting that FOXP3 may have a broader role in cancer than initially thought.
In this review, we will underscore the role of human FOXP3 in a cancer setting.
General properties of human Foxp3
Human FOXP3 gene and protein The FOXP3 gene is well conserved in mammalians (Ziegler, 2006) . The human FOXP3 gene is located on the short arm of the X chromosome and consists of 11 translated exons encoding a protein of 431 amino acids (Lopes et al., 2006) . From the N terminus, it contains a proline-rich repressor domain required for repressing the expression of target genes, a zinc-finger, a leucine zipper motif, which allows FOXP3 homo-or heterodimerization, and finally the conserved DNA-binding forkhead domain (FKH) with two sites targeting FOXP3 localization to the nucleus at its C and N terminus (Lopes et al., 2006) (Figure 1 ).
FOXP3 can be part of a large molecular complexes of B600 kDa, together with histone deacetylases, histone acetyltransferases and other transcription factors such as Runx1 Ono et al., 2007) . It associates with several transcription factors, including the nuclear factor of activated T cells to inhibit the expression of IL-2 and other proinflammatory cytokines and dampen the effector functions of T-helper cells (Bettelli et al., 2005; Rudensky et al., 2006; Wu et al., 2006) .
In contrast with mouse Treg, in which Foxp3 is only expressed as a full-length protein, human Treg express two major isoforms of FOXP3 in approximately equal amounts: a full-length isoform (FOXP3FL, apparent molecular weight: 58 kDa) that represents the ortholog of mouse Foxp3 and an alternative-splicing product lacking exon 3 (FOXP3D3, apparent molecular weight: 54 kDa) (Allan et al., 2005) . It should be emphasized that several reports refer to exon 3 as exon 2, because exon 1 is often not considered due to its position within the 5' untranslated region (Ebert et al., 2008) . FOXP3 exon 3 (aa 72-106) encodes a domain that interacts with and inhibits retinoic acid receptor-related orphan receptors (ROR)a, which leads to the expression of genes that define Th17 cells. Thus, the full-length isoform but not FOXP3D3 negatively regulates Th17 differentiation (Du et al., 2008) .
Epigenetic regulation of Foxp3 expression FOXP3 transcription is regulated by a promoter located immediately upstream to the FOXP3 transcriptional start site. Other regulatory cis-elements located between the first noncoding exons or far upstream of the transcriptional start site (B5 kb) are referred to as the intronic or upstream enhancers, respectively. These regulatory elements receive signals provided by the TCR, but their subsequent activity is affected by the methylation of the CpG sites present in promoter and intronic enhancer sequences (Josefowicz and Rudensky, 2009; Lal and Bromberg, 2009 ). These CpG sites are largely methylated in FOXP3-negative CD4 þ T cells, but also in T cells that express weakly and transiently FOXP3 and are devoid of any regulatory activity. In contrast, these CpG sites are demethylated in Tregs expressing high and stable levels of FOXP3.
Regulation of FOXP3 expression In mice, Foxp3
þ Tregs are generated in the thymus concomitantly with positive selection of conventional CD4 þ T cells. Treg differentiation requires TCR activation, involving presentation of self-antigenic peptides in association with class-II major histocompatibility complex molecules (Fontenot et al., 2005) . Costimulation through CD28 signaling is also required (Tai et al., 2005) . In humans, due to thymus involution after puberty, it is likely that the generation of Treg in the thymus is limited, at least in adults (VukmanovicStejic et al., 2006; Akbar et al., 2007) . However, circulating Treg numbers do not decrease during human life, suggesting that human Treg may not only stem from the thymus but also from the conversion of CD4 þ FOXP3 -CD25 -non-Tregs. In mice, conversion of conventional CD4 þ T cells into Foxp3 þ Treg can be obtained in vitro, but usually requires TCR activation in the presence of high concentrations of exogenous transforming growth factor (TGF)-b (Chen et al., 2003) . In contrast, TGF-b is not required for FOXP3 induction in human effector cells. The association of TCR and CD28 signaling is sufficient for inducing FOXP3 expression in human peripheral T cells, leading to an upregulation of CD25 expression and a decreased cell proliferation and IL-2 secretion (Walker et al., 2005; Ziegler, 2006) . Under these conditions, FOXP3 upregulation can be only transient and insufficient to confer immunosuppressive functions to activated T cells Wang et al., 2007) . However, authentic Treg with long-lasting FOXP3 expression and suppressive function can also be generated in the periphery. These extra-thymic Treg can be induced by an immune response specific to a cognate antigen, such as antigens provided by virus and bacteria, alloantigens or neoantigens from tumor cells, whereas Treg originated in thymus of the neonates mainly recognize selfantigens (Walker et al., 2005; Akbar et al., 2007) .
FOXP3 expression is therefore not an absolute criterion for characterizing human FOXP3-expressing CD4 þ T cells as Treg. Recently, the group of Sakaguchi (Miyara et al., 2009) high activated Treg, which were both suppressive in vitro, and CD45RA -Foxp3 low nonsuppressive T cells that were effector cells secreting high amounts of IL-2 and interferong (IFNg). Demethylation at a highly conserved region within the intronic enhancer of the FOXP3 gene was found to be a more valuable criterion than the expression of FOXP3 protein itself for discriminating Treg from activated T cells, notably in cancer patients (Wieczorek et al., 2009) .
The stability and acetylation of FOXP3 dictates Treg plasticity FOXP3 protein has a short half-life as it undergoes rapid polyubiquitination and proteasomal degradation. However, this process can be blocked by acetylation of FOXP3 lysine residues that prevents its ubiquitination (van Loosdregt et al., 2010) . Owing to FOXP3 instability or changes in its epigenetic control, Treg can lose FOXP3 expression and consequently immune suppressive activity (Wan and Flavell, 2007) , thus demonstrating the plasticity of the FOXP3 program. In particular, inflammatory condition, with the presence of high amounts of IL-6, fully converts differentiated Foxp3 þ Treg cell into Th17 cells (Xu et al., 2007; Yang et al., 2008) . This event is due to the capacity of STAT3 to downregulate the expression of FOXP3. Furthermore, adoptive transfer of Treg cells into lymphopenic hosts also leads to a loss of Foxp3 expression and their differentiation into so-called follicular T-helper cells (Tsuji et al., 2009) . Following FOXP3 downregulation, Treg can even exert effector cell activities including the production of IL-17 or IFNg (Zhou et al., 2009) . This illustrates that stability of foxp3 expression is directly affecting the plasticity of Treg.
FOXP3 controls gene expression in Treg
FOXP3 is able to bind B700 genes, of which a large number are up-or downregulated in FOXP3 þ T cells, suggesting that FOXP3 acts as both a transcriptional activator and a repressor (Zheng et al., 2007) . Binding of FOXP3 to the promoters and 5 0 regulatory regions of Ctla4 (encoding the immunomodulatory receptor CTLA-4) and Il2ra (encoding IL2 receptor-a, IL-2Ra; also called CD25) enhances their transcription, whereas binding of Foxp3 to the Il2 and Il7ra promoters facilitates repression of these genes (encoding IL-2 and IL7 receptor-a, respectively). This dual activity of FOXP3 defines characteristic features of Treg cells, which have high expression of CTLA-4 and CD25, but low expression of IL-7R and lack IL-2 production. FOXP3 also binds to the IFNg locus, suppressing IFNg expression (Chen et al., 2006) .
The molecular mechanisms by which FOXP3 controls gene expression in Treg cells involve interactions of FOXP3 with other transcription factors. For example, FOXP3 can interact with nuclear factor of activated T cells, preventing its binding to AP-1; FOXP3-nuclear factor of activated T-cell transcription factors act together to activate Ctla4 and Il2ra and antagonize Il2 expression dependent on nuclear factor of activated T cells and the transcription factor AP-1 (Wu et al., 2006) . Binding of FOXP3 to the IL-2 and IFNg genes induces active deacetylation of histone H3, a process that inhibits chromatin remodeling, impeding gene transcription. Conversely, binding of FOXP3 to the Il2ra and Ctla4 promoters results in increased histone acetylation, enhancing gene transcription (Chen et al., 2006) .
Recently, Pardoll and colleagues (Pan et al., 2009 ) demonstrated that FOXP3-dependent gene silencing involved in downregulation of IL-2 and IFNg in mouse Treg is related to FOXP3 interaction with Eos, a zincfinger transcription factor of the Ikaros family. Direct interaction of Eos and FOXP3 induces epigenetic chromatin modifications that result in gene silencing in Treg. An effect of the Eos-FOXP3 interaction in human Treg-mediated IL-2 and IFNg downregulation remains to be investigated.
These FOXP3-dependent modifications of gene expression in Treg are therefore directly linked to their capacity to promote or repress an immune response and involve various mechanisms, such as the FOXP3-dependent CTLA4 overexpression on Treg, which interacts with CD80 and CD86 costimulatory signals on dendritic cells (Tang and Bluestone, 2008; Shevach, 2009 ).
Foxp3 and Tregs in human cancers
It is now well established that FOXP3-expressing Tregs (Sakaguchi et al., 1995) are more abundant in the peripheral blood of cancer-bearing patients relatively to healthy subjects (Woo et al., 2001; Liyanage et al., 2002) .
Immunolabeling of tumor sections with antibodies directed against FOXP3 has been used to determine Treg infiltration in human cancers. A series of commercially available antibodies are currently used for immunohistochemistry labeling (Roncador et al., 2005; Woo et al., 2008; Wang et al., 2009) . Most human tumors are infiltrated by Treg, presenting as small cells, with lymphocytic morphology, and high FOXP3 labeling in their nucleus (Table 1) . FOXP3 þ cells were sometimes localized in the vicinity of tumor cells, but rather predominant in the peripheral lymphoid-enriched areas (Curiel et al., 2004; Mizukami et al., 2008; Gobert et al., 2009) . The density of FOXP3 þ cells was reported to be significantly higher in malignant than in normal tissue (Bates et al., 2006; Hiraoka et al., 2006; Miller et al., 2006; Mizukami et al., 2008) . However, it should be noted that all tumor-infiltrating FOXP3 þ cells were not inevitably Tregs because TCR activation of conventional T cell may be sufficient for inducing FOXP3 transient expression without suppressive properties, as discussed above.
Relation between Foxp3
þ T cells infiltrating cancer and clinical prognosis As FOXP3 Tregs are immunosuppressive cells, their abundance in tumor infiltrates is expected to be associated with an unfavorable clinical prognosis. Indeed, many studies reported that increased Treg infiltration in tumor bed predicted reduced survival in cancer-bearing patients (Table 1 ). In neoadjuvant breast cancer chemotherapy, we found a close relationship between complete histological response and the absence of FOXP3 cells . However, no significant relation between Treg infiltration and prognosis was found in patients bearing kidney cancer (Siddiqui et al., 2007) . Paradoxically, a high density of FOXP3 þ T-cell infiltration was correlated with a better locoregional control of the tumor in patients with head and neck carcinoma (Badoual et al., 2006) . Similarly, high numbers of tumor-infiltrating FOXP3 þ Treg are associated with improved overall survival in patients with follicular B cells (Carreras et al., 2006) or Hodgkin's lymphoma (Alvaro et al., 2005) . Recently, analysis of a large series of patients with stage II or stage III colorectal carcinoma showed that high density of FOXP3
þ T cells in tumor tissue was associated with improved survival (Salama et al., 2009) . We believe that the interaction between the different components of the tumor microenvironment and the diversity of signals provided by the tumor cells can explain these discrepancies in the prognostic studies relying on the presence of Treg in tumor infiltrates.
FOXP3
þ Treg accumulation in human cancers The mechanisms leading to FOXP3
þ Treg accumulation in the cancer microenvironment have been reviewed (Zou, 2006) . (1) Treg from the thymus, lymph nodes, bone marrow and peripheral blood express CC-chemokine receptor 4 (CCR4) and can be attracted by the abundant expression of CC-chemokine ligand 22 (CCL22, a CCR4 ligand) produced by cancer cells and tumor-infiltrating macrophages (Curiel et al., 2004; Miller et al., 2006; Mizukami et al., 2008; Gobert et al., 2009) . (2) Even if Treg are refractory to proliferation when activated by antibodies against CD3 and CD28 in vitro, they could proliferate actively when located in the tumor stroma, probably under the effect of IL-2 released in the tumor microenvironment and TCR activation by dendritic cells recognizing tumorspecific antigens (Gobert et al., 2009) . In experimental tumor models, we demonstrated that a subset of immature myeloid dendritic cells was recruited in the tumor and induced an active proliferation of Treg through TGF-b expression (Ghiringhelli et al., 2005) . (3) Conventional nonregulatory CD4 þ T cells can be converted into Treg cells in the tumor. In experimental tumors, this conversion can be induced by TGF-b, a cytokine often present at a high level in the tumor microenvironment (Zou, 2006) . A similar mechanism may take place in human tumors. For example, a human lung cancer cell line could trigger dendritic cells to produce TGF-b1 and induce the differentiation of CD4 þ T cells into Treg (Dumitriu et al., 2009 ).
þ Treg and cancer treatment Experimental data obtained with rodent tumor models demonstrate that Treg reduction can dampen tumor growth and increase the efficacy of tumor immunotherapy (Ghiringhelli et al., 2004) . The effects and limitation of targeting Treg in the treatment of cancer was recently reviewed (Zou, 2006; Curiel, 2008) . In this study, we will discuss two strategies used for the selective depletion in Treg that have been recently evaluated in clinical trials: fusion proteins associating a toxin with a ligand of a Treg surface marker and cyclophosphamide.
Denileukin diftitox or ONTAK, a recombinant IL-2 diphtheria toxin conjugate that was initially implemented for the treatment of CD25-overexpressing hematopoietic malignancies, is selectively eliminating Treg due to their constitutive expression of the IL-2 receptor a-subunit CD25 (Manoukian and Hagemeister, 2009 (Powell et al., 2007) . In rodent models, we observed that administration of a low dose cyclophosphamide selectively decreases the number of circulating Treg in cancer-bearing animals and strongly enhances the tumor response to immunotherapy (Ghiringhelli et al., 2004; Taieb et al., 2006; Roux et al., 2008) . These preclinical results were later confirmed by other investigators (Liu et al., 2007) . It was also shown that administration of low dosages of cyclophosphamide not only decreases the number of Treg, but reduces their expression of Foxp3 and their suppressive potential (Lutsiak et al., 2005) . Consequently, cyclophosphamide can be counted among the recently reported category of anticancer immunogenic chemotherapies (Haynes et al., 2008; Zitvogel and Kroemer, 2008) . These results provided impetus to use repetitive but low doses of orally administered cyclophosphamide ('metronomic treatment') for 30 consecutive days in patients with advanced metastatic tumors, which did not respond anymore to conventional chemotherapy. Even at this late stage of the disease, a selective decrease of circulating Treg was observed in all the nine treated patients with a restoration of peripheral T-cell proliferation and innate tumor cell killing activities. No objective clinical response could be measured, but the treatment was well tolerated and a stabilization of the disease was observed in some patients (Ghiringhelli et al., 2007) . Meanwhile, another team administered metronomic low dose oral cyclophosphamide for patients with hormone-resistant prostate cancer. (Gobert et al., 2009) 191 Unfavorable Colorectal carcinoma (Salama et al., 2009) 967 Favorable Cervix carcinoma (Jordanova et al., 2008) 115 Unfavorable Esophagus carcinoma (Yoshioka et al., 2008) 122 Not significant Gastric carcinoma (Mizukami et al., 2008) 80 Unfavorable (*) Head & neck carcinoma (Badoual et al., 2006) 84 Favorable Hepatocellular carcinoma (Gao et al., 2007) 302 Unfavorable Kidney carcinoma (Siddiqui et al., 2007) 170 Not significant Lymphoma (B cell) (Carreras et al., 2006) 98 Favorable Lymphoma (Hodgkin) (Alvaro et al., 2005) 257 Favorable Ovary carcinoma (Curiel et al., 2004) 104 Unfavorable Pancreatic carcinoma (Hiraoka et al., 2006) 198 Unfavorable
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The treatment was considered as well tolerated and an objective clinical or biological (PSA) response was observed in 34.5% of the patients (Lord et al., 2007) .
FOXP3 expression in human cancer cells
Foxp3 protein expression was thought to be restricted to the lymphocyte lineage (Fontenot et al., 2005) . However, this expression was recently demonstrated in nonhematopoietic cells of various kinds and also in cancers cells of a nonhematopoietic origin, raising questions about its role in carcinogenesis and the immune response in these different locations.
FOXP3 expression in normal and cancerous human cells
Foxp3 expression in noncancerous epithelial cells was investigated in Rag2 À/À mice, which are notably devoid of T lymphocytes, and in mice with the Scurfy mutation that deletes Foxp3 expression (Chen et al., 2008) . This study revealed expression of Foxp3 mRNA and protein in the nuclei of epithelial cells in the breast, lung and prostate, but not in the liver, kidney and intestine.
In humans also, FOXP3 mRNA or protein were recently reported to be expressed in a variety of normal and cancerous cells in addition to Treg. When FOXP3 expression was compared in human cancer cells and in their normal homologs, two opposite situations were found. In the first one, FOXP3 expression was restricted to the tumor cells. Normal pancreatic duct cells were devoid of FOXP3 expression, but FOXP3 was detected by immunohistochemistry in human pancreatic cancer cells (Hinz et al., 2007) . Cancer cell staining was cytoplasmic in most patients, whereas in others, it was predominantly nuclear. Interestingly, FOXP3-expressing pancreatic cancer cell lines strongly inhibited the proliferation of anti-CD3/anti-CD28-stimulated T cells without impeding their activation, suggesting that FOXP3 expression in cancer cells might trigger a mechanism of immune evasion. FOXP3 was also found to be expressed by human melanoma cells but was not detected in normal melanocytes (Ebert et al., 2008) . Reverse transcription-PCR confirmed the presence of FOXP3 transcripts in melanoma cells that expressed the two isoforms found in human Treg, including the full-length variant. Immunohistochemistry with anti-FOXP3 on melanoma tissue sections showed a nuclear labeling of melanoma cells. FOXP3 was widely expressed in human melanoma cell lines.
In contrast, FOXP3 was expressed in normal epithelial cells of human breast and prostate, but downregulated in the corresponding cancer cells. The levels and isoforms of the FOXP3 transcripts were analyzed in a panel of primary normal human mammary epithelial cells, and in malignant breast cancer cell lines (Zuo et al., 2007b) . FOXP3 transcripts with the same two isoforms as found in Treg were observed in noncancerous epithelial cells. Many cancer cell lines expressed detectable level of FOXP3, although they did not express the full-length transcript but rather transcript with exon 3, exon 4 and/or exon 8 deletion. Protein detection using immunohistochemistry demonstrated that about 80% of normal breast samples expressed FOXP3 in the epithelial cell nuclei, whereas 20% of cancerous tissues only showed nuclear staining. In some tumor samples, fluorescence in situ hybridization demonstrated a complete deletion of the FOXP3 locus. FOXP3 expression was also investigated in normal and cancerous human prostatic epithelial cells (Wang et al., 2009 ). FOXP3 nuclear staining of epithelial cells was observed in all samples of normal prostate tissues tested, but only in 30% of the prostate cancer samples. In these cancer samples, FOXP3 cDNA harbored genetic mutations or deletions.
Antioncogenic effect of FOXP3
In human breast and prostate, the overwhelming difference between normal and cancerous epithelial cells in FOXP3 expression strongly suggests a relationship between FOXP3 downregulation and cancer development (Wang et al., 2009) . FOXP3 gene is located on the X chromosome. In mammals, both male and female cells carry only one active X chromosome, because males have only one X chromosome and in females one of the X chromosomes undergoes inactivation by transcriptional silencing. This inactivation is initiated early in embryonic stem-cell differentiation, the choice of the inactivated X chromosome is random and heritable through subsequent rounds of cell division, leading female tissues to a mosaic of cells where either the paternal or the maternal X chromosome is active. Owing to this X-chromosome unisomy, a single genetic hit can transform a cell if it damages a tumor suppressor gene located on the X chromosome (Spatz et al., 2004; Medema and Burgering, 2007) . As reported above, FOXP3 was often altered in human breast or prostate cancers, undergoing deletion or mutations. Recently, three reports demonstrated that FOXP3 was a tumor suppressor gene in the breast and prostate. Wild-type FOXP3 from normal cells, but not mutated FOXP3 from cancer cells, bound to and repressed two oncogenes involved in mammary carcinogenesis, HER-2 and SKP2 (Zuo et al., 2007a, b) and oncogene c-MYC involved in prostate carcinogenesis (Wang et al., 2009) . The FKH DNA-binding domain of FOXP3 interacted with motifs in the promoter of these oncogenes. HER-2 is a member of a family of genes encoding transmembrane receptors for growth factors. Between 15 and 20% of invasive breast cancers overexpress HER-2 and have a worse prognosis than HER-2-negative tumors, a greater resistance to conventional chemotherapy, but a high sensitivity to Trastuzumab, a humanized monoclonal antibody against HER-2 (Burstein, 2005) . The S-phase kinaseassociated protein SKP2 is involved in the ubiquitination and degradation of the cdk-inhibitor p27 and has an oncogenic potential in breast epithelial cells. SKP2 is overexpressed in nearly 50% of breast carcinomas (Signoretti et al., 2002) . C-MYC is involved with ras in prostate carcinogenesis (Thompson et al., 1989) and is overexpressed in 80% of the prostate cancer samples. A significant correlation was observed between FOXP3 downregulation and HER-2 and SKP2 or cMYC overexpression in breast and prostate cancer cells (Zuo et al., 2007a (Zuo et al., , 2007b Wang et al., 2009) .
In short, when expressed in breast and prostate cancer cells, FOXP3 gene may act as a tumor suppressor by repressing various oncogenes. However, due to its location on the X chromosome, it is also an appropriate target for a single hit process that will suppress its expression or function, release the repressed oncogenes and initiate transformation (Figure 2) . Interestingly, transfection of the full-length FOXP3 cDNA in human breast or prostate cancer cell lines repressed colony formation, thus further demonstrating a tumor suppressor role for FOXP3 (Zuo et al., 2007b; Wang et al., 2009) .
Nuclear or cytoplasmic FOXP3 expression in cancer cells FOXP3 is constitutively expressed in the nucleus of human Treg. A nuclear localization of FOXP3 was also reported for most human normal and cancer cells expressing this factor (Zuo et al., 2007b; Ebert et al., 2008; Wang et al., 2009 ). However, a predominant cytoplasmic FOXP3 labeling was reported for human pancreatic cancer cells (Hinz et al., 2007) . In a recent work dealing with two large series of breast cancer specimens, immunohistological FOXP3 staining was localized predominantly in the tumor cell cytoplasm, whereas a few specimens showed only nuclear staining (Merlo et al., 2009) . Finally, in a series of 103 human breast cancers selected for HER-2 oncogene overexpression, FOXP3 was observed in cancer cells of 59 specimens, but only with a cytoplasmic localization, without any nuclear extension (Figure 3 ) (Ladoire et al.,
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Single hit 2010). At present, it is difficult to interpret the significance of this cytoplasmic localization, which could be due to a mutation or a deletion of the nuclear localization signals surrounding the FKH domain of FOXP3. Wang et al. (2009) observed that three of the four FOXP3 mutants obtained from human pancreatic carcinomas disrupted their translocation into nuclei but localized in the cytoplasm.
Effect of DNA-damaging agent and p53 on FOXP3 expression in cancer cells Mechanisms that regulate FOXP3 expression in tumor cells remain largely unexplored. A recent report demonstrated that FOXP3 expression is increased in some human breast and colon carcinoma cell lines on exposure to DNAdamaging agents, such as doxorubicin, etoposide and cisplatin (Jung et al., 2010) . Interestingly, this increase in FOXP3 expression was documented only in cell lines expressing wild-type p53. FOXP3 knockdown blunted the p53-mediated growth inhibitory response to DNA-damaging agents, thus implicating FOXP3 as a key determinant of cell fate in p53-dependent DNA-damage responses.
Conclusion
Initially considered as a stable and reliable marker of CD4 and CD25-expressing Treg, Foxp3 should now be considered in a more critical approach, particularly in its relationship with human cancers. An accumulation of FOXP3 þ T cells is observed in the immune infiltrate of many cancer types, but its relationship with the clinical prognosis could be beneficial or detrimental according to the type of malignancies considered. In contrast to their mouse homologs, human conventional CD4 þ T cells can express transiently FOXP3 without acquiring immunosuppressive properties on TCR activation, and could thus represent a part of the tumor-infiltrating FOXP3 þ T cells. FOXP3 can also be expressed in varieties of normal or malignant cells outside Treg. This expression is usually moderate, can be nuclear and/or cytoplasmic and the role of FOXP3 in these cells remains largely undetermined. However, at least in breast and prostate epithelial cells, FOXP3 has the role of a tumor suppressor repressing several major oncogenes. FOXP3 gene damaging, facilitated by its localization on the X chromosome, release oncogenic activity and carcinogenesis.
Thus, FOXP3 is a multifaceted factor of cancer biology, having a tumor-enhancing role through Treg and their effect on tumor tolerance, but also suppressing carcinogenesis as a potent repressor of several oncogenes.
